文献速递妇科

聚焦超声消融手术联合宫腔镜治疗最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤的临床应用价值

[Clinical application value of combined focused ultrasound ablation surgery and hysteroscopy in the treatment of solitary type Ⅱ submucosal uterine fibroids with maximum diameter more than 5 cm].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2025-01-01

回顾性分析35例最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤患者,先行聚焦超声消融手术(FUAS)再择期宫腔镜手术。FUAS后肌瘤体积缩小、血红蛋白上升、经量评分下降;宫腔镜一次性切除率100.0%,术后3个月经量评分降至1分、血红蛋白升至(118.7±5.6)g/L,无肌瘤残留。

要点

  • FUAS预处理后肌瘤中位消融率90.7%,中位体积缩小率76.03%,无并发症。
  • 宫腔镜一次性切除率100.0%(35/35),1例发生稀释性低钠血症。
  • 术后3个月经量评分均降至1分,血红蛋白(118.7±5.6)g/L,无肌瘤残留。

核心结论

  • FUAS联合宫腔镜手术可有效治疗最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤,为患者提供一种新的治疗选择。

研究设计与样本

  • 回顾性分析2020年6月至2023年12月青岛市妇女儿童医院收治的35例接受FUAS联合宫腔镜手术治疗的最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤患者的临床资料。

主要发现

  • 35例患者年龄(36.7±6.6)岁,肌瘤最大径中位数56 mm(范围51~80 mm),经量评分中位数5分(范围3~5分),合并贫血34例(97.1%,34/35),血红蛋白(83.1±13.8)g/L。
  • 35例均先接受FUAS,消融率中位数90.7%(范围69.7%~97.9%),无并发症;FUAS后肌瘤体积均缩小,体积缩小率中位数76.03%(范围30.57%~87.22%)。
  • FUAS后3~14个月(中位数5个月)行宫腔镜手术,一次性切除率100.0%(35/35),1例发生稀释性低钠血症。
  • FUAS后肌瘤最大径线和体积均较前显著缩小(Z=-5.171,P<0.001;Z=-5.159,P<0.001),血红蛋白较前显著上升(t=-8.657,P<0.001),经量评分中位数降至2分(范围1~3分)较前显著下降(Z=-5.292,P<0.001)。
  • 宫腔镜术后3个月所有患者无贫血症状,血红蛋白(118.7±5.6)g/L较术前显著上升(t=-9.258,P<0.001),经量评分均降至1分较术前显著下降(Z=-4.786,P<0.001),经阴道超声均未提示肌瘤残留。

临床怎么用

  • 作者认为FUAS联合宫腔镜手术可有效治疗最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤,为患者提供一种新的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the effectiveness and application value of focused ultrasound ablation surgery (FUAS) combined with hysteroscopic surgery in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm. Methods: Clinical data of 35 patients with a single type Ⅱ submucosal uterine fibroid with maximum diameter greater than 5 cm who underwent FUAS combined with hysteroscopic surgery at Qingdao Women and Children's Hospital from June 2020 to December 2023 were collected. The clinical characteristics, treatments and treatment outcomes were retrospectively analyzed. Results: (1) Clinical characteristics: the mean age of the 35 patients was (36.7±6.6) years, with a median maximum diameter of fibroids of 56 mm (range: 51-80 mm). All patients presented with symptoms of menorrhagia, median menstrual bleeding score was 5 points (ranged from 3 to 5 points), and 34 cases (97.1%, 34/35) had concomitant anemia, the mean hemoglobin was (83.1±13.8) g/L of 35 patients. (2) Treatments: all 35 patients underwent FUAS treatment initially, with a lesion ablation rate ranging from 69.7% to 97.9% (median:90.7%), and no complications occurred. After FUAS treatment, the volume of fibroids decreased in all patients, with a volume reduction rate ranging from 30.57% to 87.22% (median:76.03%). Hysteroscopic surgery was performed 3-14 months (median: 5 months) after FUAS to remove the necrotic fibroid tissue, achieving a 100.0% (35/35) fibroid resection rate. Only 1 patient developed complications of hyperhyderation syndrome during hysteroscopic surgery, and no complications occurred in the remaining patients. (3) Evaluation of efficacy: after FUAS pretreatment, the maximum diameter of fibroids in the 35 patients decreased significantly (Z=-5.171, P<0.001), as did the volume of fibroids (Z=-5.159, P<0.001). The hemoglobin level increased significantly compared to the level before FUAS in all cases (t=-8.657, P<0.001), and median menstrual bleeding score decreased to 2 points (range: 1-3 points), significantly lower than original level (Z=-5.292, P<0.001). At the 3-month follow-up after hysteroscopic surgery, all patients were free of anemia symptoms, with menstrual bleeding scores totally decreased to 1 point, significantly lower than that before hysteroscopic surgery (Z=-4.786, P<0.001); hemoglobin level [(118.7±5.6) g/L] significantly increased compared to that before hysteroscopic surgery (t=-9.258, P<0.001). All patients underwent gynecological transvaginal ultrasound re-examination, which did not reveal any residual fibroids. Conclusion: FUAS combined with hysteroscopic surgery is effective in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm, providing a new treatment option for patients. 目的: 探讨聚焦超声消融手术(FUAS)联合宫腔镜手术治疗最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤的有效性及临床应用价值。 方法: 收集2020年6月至2023年12月青岛市妇女儿童医院收治的35例接受FUAS联合宫腔镜手术治疗的最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤患者的临床资料,回顾性分析其临床特点、治疗情况及治疗效果。 结果: (1)临床特点:35例患者的年龄为(36.7±6.6)岁,肌瘤最大径线的中位数为56 mm(范围:51~80 mm);均有月经过多症状,经量评分的中位数为5分(范围:3~5分),其中合并贫血34例(97.1%,34/35),35例的血红蛋白含量为(83.1±13.8)g/L。(2)治疗情况:35例患者均先接受FUAS治疗,消融率的中位数为90.7%(范围:69.7%~97.9%),无并发症发生;35例患者在FUAS治疗后肌瘤体积均较FUAS治疗前缩小,体积缩小率的中位数为76.03%(范围:30.57%~87.22%)。FUAS治疗后3~14个月(中位数为5个月)择期行宫腔镜手术清除缩小后的坏死肌瘤组织,宫腔镜手术一次性切除率为100.0%(35/35)。宫腔镜手术中除1例患者发生稀释性低钠血症,其余患者无并发症发生。(3)疗效评价:经FUAS预处理后,35例患者的肌瘤最大径线和肌瘤体积均较FUAS治疗前显著缩小(Z=-5.171,P<0.001;Z=-5.159,P<0.001),血红蛋白含量较FUAS治疗前显著上升(t=-8.657,P<0.001);经量评分中位数为2分(范围:1~3分),较FUAS治疗前显著下降(Z=-5.292,P<0.001)。宫腔镜手术后3个月复查,所有患者均无贫血症状,血红蛋白含量[(118.7±5.6)g/L]较宫腔镜手术前显著上升(t=-9.258,P<0.001);经量评分均降为1分,较宫腔镜手术前显著下降(Z=-4.786,P<0.001);所有患者复查经阴道超声,均未提示肌瘤残留。 结论: FUAS联合宫腔镜手术可有效治疗最大径>5 cm单发Ⅱ型黏膜下子宫肌瘤,为患者提供了一种新的治疗选择。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Cheng HY, Sang CM, Kang YJ, et al. [Clinical application value of combined focused ultrasound ablation surgery and hysteroscopy in the treatment of solitary type Ⅱ submucosal uterine fibroids with maximum diameter more than 5 cm]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40419350. doi:10.3760/cma.j.cn112141-20241022-00566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。